Anticonvulsant treatments of dysphoric mania: a trial of gabapentin, lamotrigine and carbamazepine in Iran.

Neuropsychiatric Disease and Treatment
Naghmeh MokhberAllan H Young

Abstract

The treatment of dysphoric mania is challenging given the need to treat symptoms of both depression and mania simultaneously without provoking any clinical exacerbation. The newer antiepileptic drugs such as gabapentin, lamotrogine, and carbamazepine are often used as adjuncts to either lithium or valproic acid in the treatment of bipolar disorder. We decided to undertake a monotherapy trial because previous evidence suggested mixed states may be more responsive to anticonvulsants than more traditional antimanic agents. 51 patients with a DSM IV diagnosis of dysphoric mania were randomized to three groups comprising gapbapentin, lamotrogine or carbamazepine and followed for 8 weeks. Psychiatric diagnosis was verified by the structural clinical interview for the DSM-IV (SCID). The MMPI-2 in full was used to assess symptoms at baseline and 8 weeks. All three groups showed significant changes in MMPI-2 scores for depression and mania subscales. Gabapentin showed the greatest change in depression symptom improvement relative to lamotrogine and carbamazepine, respectively. Although manic symptoms improved overall, here were no differences between groups in the degree of manic symptom improvement.

References

Feb 1, 1992·Journal of Clinical Psychopharmacology·J ClothierT Freeman
May 1, 1995·The British Journal of Psychiatry : the Journal of Mental Science·C Short, L Cooke
Nov 1, 1996·Psychopharmacology·R M PostM A Frye
Jun 25, 1998·Journal of Child and Adolescent Psychopharmacology·C A SoutulloP E Keck
Jul 8, 1998·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·C L Bowden
Oct 21, 1998·Neuropsychobiology·J R CalabreseS E Kimmel
Oct 28, 1998·Journal of Psychiatric Research·A ErfurthJ Walden
Dec 19, 1998·Journal of Affective Disorders·F CassidyB J Carroll
Jul 10, 1999·Fortschritte der Neurologie-Psychiatrie·H GrunzeJ Walden
Oct 8, 1999·Journal of Affective Disorders·L T YoungR T Joffe
Oct 19, 1999·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·C L BowdenT Suppes
Oct 19, 1999·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·M Berk
Jan 25, 2000·The British Journal of Psychiatry : the Journal of Mental Science·F M LewekeC E Elger
May 29, 2000·Harvard Review of Psychiatry·S N Ghaemi, S Gaughan
Dec 12, 2000·European Psychiatry : the Journal of the Association of European Psychiatrists·E VietaC Gastó
Mar 21, 2001·Bipolar Disorders·L L AltshulerR Post
Jul 5, 2002·CNS Drugs·Kathryn J Macdonald, L Trevor Young
Oct 22, 2002·Expert Opinion on Pharmacotherapy·Charles L Bowden
Dec 14, 2002·Bipolar Disorders·Po W WangTerence A Ketter
Dec 31, 2002·The American Journal of Psychiatry·Howard C MargoleseGuy Chouinard
Mar 18, 2003·Journal of Clinical Psychopharmacology·Robert W BakerGary D Tollefson
Jun 5, 2003·Journal of Affective Disorders·Mauro Giovanni CartaBernardo Carpiniello
Jun 17, 2003·Journal of Geriatric Psychiatry and Neurology·M Awais SethiD P Devanand
Oct 1, 2004·Journal of Personality Assessment·James N Butcher
Apr 19, 2005·Acta Psychiatrica Scandinavica. Supplementum·D J MuzinaJ R Calabrese
May 19, 2005·Bipolar Disorders·Stephanie KrügerPeter Bräunig

❮ Previous
Next ❯

Methods Mentioned

BETA
contraception

Software Mentioned

SPSS

Related Concepts

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

© 2022 Meta ULC. All rights reserved